BAY1238097 Inhibitor

Name: BAY1238097 Inhibitor; MyBioSource
Brand: MyBioSource
SKU: MBS5753788
Availability: InStock
Rating: 5 (10 reviews)

For Research Use Only. Not for use in diagnostic procedures. Catalog #: MBS5753788

BAY1238097 is a potent and selective inhibitor of BET binding to histones and has strong anti-proliferative activity in differentmM (multiple myeloma) and AML (acute myeloid leukemia) models through down-regulation of c-Myc levels and its downstream… More details

Please Inquire

Product Documentation

Sample Manual Insert View PDF

Testing Data View PDF

Certificate of Analysis (COA) View PDF

QC Report View PDF

Material Safety Data Sheet View PDF

Technical Datasheet View PDF

Protocol View PDF

Product Overview

Online Datasheet in PDF

Product Name

BAY1238097, Inhibitor

Full Product Name

BAY1238097

Product Gene Name

BAY1238097, inhibitor

Form/Format

Solid. Powder

Purity/Purification

98.00%

Preparation and Storage

Store at -20 degree C for 3 years powder
-80 degree C for 2 years in solvent

Molecular Weight

451.56

Solubility

DMSO: 150mg/mL (332.18mM) Need ultrasonic
(<1mg/ml refers to the product slightly soluble or insoluble)

Formula

C25H33N5O3

SMILES

O=C(N1N=C(C2=CC=C(N3CCN(C)CC3)C=C2)C4=CC(OC)=C(OC)C=C4C[C@@H]1C)NC

CAS Number

1564268-08-1

Target & IC50

BET in a TR-FRET assay: ic50 <100nM

In Vitro

BAY 1238097 is well tolerated at 10-15mg/kg applied daily over 9-14 days in different disease models, with no obvious toxicity[1][2] and it shows strong efficacy in the AML andmM models. BAY 1238097 has in vivo anti-tumour activity in lymphoma models[1][2].

Product Categories/Family for BAY1238097, inhibitor

Chromatin/Epigenetic; Epigenetic Reader Domain; Epigenetics

Product References and Citations for BAY1238097, inhibitor

Lejeune, P., et al. (2015) Abstract 3524: BAY 1238097, a novel BET inhibitor with strong efficacy in hematological tumor models. Cancer Research, 75(15 Suppl), 884.
Lejeune, P., et al. (2015) Abstract 3524: BAY 1238097, a novel BET inhibitor with strong efficacy in hematological tumor models. Cancer Research, 75(15 Suppl), 884.
Bernasconi E, et al. Preclinical evaluation of the BET bromodomain inhibitor BAY 1238097 for the treatment,of lymphoma. Br J Haematol. 2017 Sep;178(6):936-948.
Bernasconi E, et al. Preclinical evaluation of the BET bromodomain inhibitor BAY 1238097 for the treatment,of lymphoma. Br J Haematol. 2017 Sep;178(6):936-948.

Other Notes

Small volumes of BAY1238097, inhibitor vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Searchable Terms for BAY1238097 purchase

MBS5753788 is an inhibitor targeting BAY1238097.